Aminosalicylate use Increases Corticosteroid Exposure and Decreases Biologic Durability in Pediatric Crohn's Disease: GI Signals

IBD prospective cohort · n=679 · Aug 21, 2026 · Clin Gastro Hep · IF 16.2

Aminosalicylate use Increases Corticosteroid Exposure and Decreases Biologic Durability in Pediatric Crohn's Disease.

Practice-changingCrohn's diseasebiologicsanti-TNFpediatric

Clinical takeawayAvoid 5-ASA monotherapy in newly diagnosed pediatric Crohn's disease. Prioritize early anti-TNF therapy to reduce cumulative corticosteroid exposure, improve biologic durability once escalation occurs, and reduce perianal disease risk.

What it foundEarly 5-ASA monotherapy in pediatric Crohn's disease was associated with greater systemic corticosteroid use (p=0.036), delayed biologic initiation (~11 months), and a 4.47-fold increased risk of biologic discontinuation among escalators (95% CI 1.28-15.65, p=0.029); early anti-TNF therapy protected against perianal disease (OR 0.24 [95% CI 0.06-0.93], p=0.039).

ContextThis extends prior evidence that 5-ASA lacks efficacy in Crohn's disease (demonstrated in randomised trials) by showing that 5-ASA use also increases harm: greater steroid exposure and inferior long-term therapy outcomes. The study addresses a persistent practice gap: 18% of the cohort still received 5-ASA monotherapy despite documented lack of benefit.

Emergingsuggested applicable standard· European Crohn's and Colitis Organisation (ECCO), "ECCO Guidelines on Inflammatory Bowel Disease and Malignancies," Journal of Crohn's and Colitis, 2023

Decision at stakeTiming of biologic therapy initiation relative to initial monotherapy in newly diagnosed pediatric Crohn's disease

Before starting a biologic or immunomodulator in IBD or rheumatology patients, complete prestart safety screening: TB screening (IGRA preferred, treat latent TB before starting), hepatitis B (HBsAg/HBcAb/HBsAb with drug-class risk-stratified antiviral prophylaxis or monitoring), hepatitis C, HIV, Strongyloides serology for endemic-region patients, vaccination review with live vaccines given before starting, and baseline labs. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Before starting a biologic or immunomodulator in IBD or rheumatology patients, complete prestart safety screening: TB screening (IGRA preferred, treat latent TB before starting), hepatitis B (HBsAg/HBcAb/HBsAb with drug-class risk-stratified antiviral prophylaxis or monitoring), hepatitis C, HIV, Strongyloides serology for endemic-region patients, vaccination review with live vaccines given before starting, and baseline labs. Delay initiation for active infection, active/untreated TB, untreated HBV, or near-term pregnancy plans for JAK/methotrexate/ozanimod. Active or prior malignancy is not a blanket reason to delay therapy: the decision requires cancer- and drug-specific assessment (cancer type, stage, prognosis, and treatment status weighed against the specific agent) made jointly with oncology in a multidisciplinary setting, not a universal hold, when IBD activity needs control most therapies can be continued or initiated (gut-selective vedolizumab has the most reassuring cancer-recurrence data), thiopurines are preferably withdrawn in patients with active cancer, and a fixed (e.g., 5-year) delay before restarting therapy after cancer is no longer recommended.

European Crohn's and Colitis Organisation (ECCO), "ECCO Guidelines on Inflammatory Bowel Disease and Malignancies," Journal of Crohn's and Colitis, 2023 · reviewed 2026-07-23 ↗

Patel PV … BISCUIT Study Team · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink